Abstract
Objective To observe the clinical efficacy of qinghuang powder in the treatment of MDS-RCMD. Methods Samples were collected from 308 MDS-RCMD patients who were treated in Xiyuan Hospital from Sep 2007 to Dec 2014. Peripheral blood neutrophils(ANC), hemoglobin(Hb), platelets(Plt), primitive bone marrow cells and chromosome karyotype were chosen as the main evaluation indexes to analyze the treatment effect. Results The ANC, Hb and Plt of patients were increased significantly after treatment(P 0.05), but the statistically significant differences were observed between WBC and Hb, Plt and Hb(P < 0.01). After treatment for the 308 patients, rates of complete remission, hematology progress, stability and disease progression were 7.5 %(23 cases), 52.6 %(162 cases), 23.7 %(73 cases), and 16.2 %(50 cases), respectively. According to cytogenetic risk(IPSS), the 308 patients were divided into three groups, namely favorable group, intermediate group and unfavorable group. Patients in favorable group had better clinic efficacy than in that in unfavorable group(P < 0.05). Conclusion Qinghuang powder combined with Bupi Yishen Decoction showed effectiveness in the treatment of MDS-RCMD and improved effect of Hb better than that of ANC or Plt. Key words: Myelodysplastic syndromes; Refractory cytopenia with multilineage dysplasia; Qinghuang powder; Treatment outcome
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
